Medical Devices Limited announced that the Australian Stroke Alliance, of which the company is a commercial collaborator, has been successful in its Stage 2 Medical Research Future Fund bid. Led by the Australian Stroke Alliance Limited, the consortium has brought together leaders across the healthcare sector to propose a transformative research program that aims to develop, test and implement breakthrough portable imaging technologies to transform access to early pre-hospital treatments for urban, rural and indigenous populations. The ASA has been advised that its competitive MRFF bid to fund a 5-year program to transform pre-hospital stroke care has been successful. EMVision has been advised by the ASA that it will receive $8 million of this non-dilutive cash funding in staged payments weighted to the earlier years of the program. Any funding advanced is contingent on the ASA executing a Funding Agreement with the MRFF, EMVision executing a Project Agreement with the ASA and satisfaction of conditions to be agreed with the ASA, including that the project is progressing in a manner that warrants continued funding at each stage. The total awarded by the federal government across the MRFF stage 2 program was $100m and the ASA received $40m. The ASA also commits to exploring the joint pursuit of further collaborative grant funding opportunities such as MRFF, CRC or NHMRC schemes with EMVison, as they arise.